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Abstract
Background: A reliable and inexpensive noninvasive marker of hepatic fibrosis is required in patients with
nonalcoholic fatty liver disease (NAFLD). FIB4 index (based on age, aspartate aminotransferase [AST] and alanine
aminotransferase [ALT] levels, and platelet counts) is expected to be useful for evaluating hepatic fibrosis. We
validated the performance of FIB4 index in a Japanese cohort with NAFLD.
Methods: The areas under the receiver operating characteristic curves (AUROC) for FIB4 and six other markers
were compared, based on data from 576 biopsy-proven NAFLD patients. Advanced fibrosis was defined as stage 3-
4 fibrosis. FIB4 index was assessed as: age (yr) × AST (IU/L)/(platelet count (10
9/L) × √ALT (IU/L))
Results: Advanced fibrosis was found in 64 (11%) patients. The AUROC for FIB4 index was superior to those for the
other scoring systems for differentiating between advanced and mild fibrosis. Only 6 of 308 patients with a FIB4
index below the proposed low cut-off point (< 1.45) were under-staged, giving a high negative predictive value of
98%. Twenty-eight of 59 patients with a FIB4 index above the high cut-off point (> 3.25) were over-staged, giving
a low positive predictive value of 53%. Using these cutoffs, 91% of the 395 patients with FIB-4 values outside 1.45-
3.25 would be correctly classified. Implementation of the FIB4 index in the Japanese population would avoid 58%
of liver biopsies.
Conclusion: The FIB4 index was superior to other tested noninvasive markers of fibrosis in Japanese patients with
NAFLD, with a high negative predictive value for excluding advanced fibrosis. The small number of cases of
advanced fibrosis in this cohort meant that this study had limited power for validating the high cut-off point.
Background
Type 2 diabetes mellitus is associated with nonalcoholic
fatty liver disease (NAFLD) in clinical practice. NAFLD
includes a wide spectrum of liver diseases ranging from
simple steatosis, which is usually a benign and non-pro-
gressive condition, to nonalcoholic steatohepatitis
(NASH), which can progress to liver cirrhosis (LC) and
hepatocellular carcinoma (HCC) in the absence of sig-
nificant alcohol consumption [1-4]. Liver biopsy remains
a reliable tool for the diagnosis of NASH [1,5,6], and
the most sensitive and specific method for providing
prognostic information. However, it may not be practi-
cal to perform liver biopsies in every patient with
NAFLD to ascertain the presence of NASH [6]. More-
over, biopsies are associated with significant limitations
such as pain, risk of severe complications, sampling
errors [7,8], cost, and patient unwillingness to undergo
invasive testing. Since it is not easy to distinguish simple
steatosis from NASH in diabetes clinics, simple scoring
systems to derive progressive NASH are required.
Numerous noninvasive panels of tests have been devel-
oped to stage liver disease, including a combination of
clinical and routine laboratory parameters, as well as
specialized tests involving direct markers of fibrosis and
elastography [9-20]. Of these, the BAAT (body mass
i n d e x[ B M I ] ,a g e ,a l a n i n ea m i n o t r a n s f e r a s e[ A L T ] ,
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any medium, provided the original work is properly cited.triglycerides) [14], European liver fibrosis (ELF) score
[10], Fibrotest (BioPredictive, Paris, France) [9], Fibros-
can (Echosens, Paris, France) [12], acoustic radiation
force impulse elastography (Mochida Siemens Medical
System Co. Ltd., Tokyo, Japan) [15], hyaluronic acid
(HA) [16,17], type IV collagen 7S [18], BARD (BMI,
aspartate aminotransferase [AST]/ALT ratio [AAR], dia-
betes mellitus [DM]) [19], N (Nippon) score [20] and
the NAFLD fibrosis score (NFS) [21] have been tested
in subjects with NAFLD.
The FIB4 index was developed as a noninvasive panel
to stage liver disease in subjects with human immuno-
deficiency virus and hepatitis C virus (HCV) co-infection
[22]. It relies on patient age, AST, ALT, and platelet
count, which are routinely measured and are thus avail-
able for virtually all subjects with liver disease. This
index has also been independently validated in subjects
with HCV infection alone [23]. It has recently been
demonstrated that its performance characteristics for
the diagnosis of advanced fibrosis in NAFLD are better
than those of other similar panels that do not require
additional testing [24]. However, 74% of the subjects
enrolled in the study were Caucasian, and validation of
the FIB4 index in other ethnic groups is required before
it can be applied globally. In this study, we therefore
aimed to assess the accuracy of the FIB4 index for pre-
dicting advanced liver fibrosis in a cohort of Japanese
patients with NAFLD.
Methods
Patients
A total of 576 patients with well-characterized and liver-
biopsy-confirmed NAFLD between 2002 and 2008 were
enrolled from the Japan Study Group of NAFLD (JSG-
NAFLD), which includes nine hepatology centers in
Japan: Center for Digestive and Liver Diseases, Nara
City Hospital; Division of Gastroenterology, Yokohama
City University Graduate School of Medicine; Depart-
ment of Medicine and Molecular Science, Graduate
School of Biomedical Sciences, Hiroshima University;
Department of Gastroenterology and Hepatology, Kochi
Medical School; Department of Internal Medicine, Saga
Medical School, Saga University; Department of Hepa-
tology, Graduate School of Medicine, Osaka City Uni-
versity; Department of Gastroenterology and
Hepatology, Kyoto Prefectural University of Medicine;
Division of Gastroenterology and Hematology/Oncology,
Department of Medicine, Asahikawa Medical College;
and Hepatology Center, Saiseikai Suita Hospital. All
patients were also involved in the previous JSG-NAFLD
study [25].
The diagnosis of NAFLD was based on the following
criteria: (1) liver biopsy showing steatosis in at least 5%
of hepatocytes [26]; and (2) appropriate exclusion of
liver diseases of other etiologies, including viral hepatitis,
autoimmune hepatitis, drug-induced liver disease, pri-
mary biliary cirrhosis, biliary obstruction, hemochroma-
tosis, Wilson’sd i s e a s e ,o ra-1-antitrypsin- deficiency-
associated liver disease. Patients who consumed > 20 g
alcohol per day and patients with evidence of decom-
pensated LC or HCC were excluded. Written informed
consent was obtained from all patients at the time of
liver biopsy, and the study was conducted in accordance
with the Helsinki Declaration [27]. The study protocol
was approved by the ethical committee of Nara City
Hospital in Nara, Japan.
Anthropometric and laboratory evaluation
Venous blood samples were taken in the morning after
a 12-h overnight fast. Laboratory evaluations in all
patients included a blood cell count and measurement
of AST, ALT, g-glutamyl transpeptidase (GGT), choli-
nesterase (ChE), total cholesterol, triglyceride, high-den-
sity lipoprotein (HDL) cholesterol, albumin, fasting
plasma glucose (FPG), immunoreactive insulin (IRI), and
ferritin. These parameters were measured using standard
clinical chemistry techniques. BMI was also calculated;
obesity was defined as BMI > 25, according to the cri-
teria of the Japan Society for the Study of Obesity [28].
Patients were assigned a diagnosis of DM if they had
documented use of oral hypoglycemic medication, a ran-
dom glucose level > 200 mg/dL, or FPG > 126 mg/dL
[29]. Hypertension was defined as a systolic blood pres-
sure ≥ 130 mmHg or a diastolic blood pressure ≥ 85
mmHg or by the use of antihypertensive agents. Dyslipi-
demia was defined as serum concentrations of triglycer-
ides ≥ 150 mg/dL or HDL cholesterol < 40 mg/dL and
< 50 mg/dL for men and women, respectively, or by the
use of specific medication [30]. Based on a review of the
literature, the following scores were calculated for each
patient: FIB4 [22], AAR, AST to platelet ratio index
(APRI) [31], age-platelet index (AP index) [32], BARD
score [19], N score [20], and NFS [13]. The values for
the upper limit of normal were set according to the
International Federation of Clinical Chemistry: AST 35
U/L for men, 30 U/L for women, and were comparable
to the values used in other analyses. The specific formu-
lae used to determine these scores are shown in Table 1.
Histologic evaluation
All patients enrolled in this study underwent percuta-
neous liver biopsy under ultrasonic guidance. The liver
specimens were embedded in paraffin and stained with
hematoxylin and eosin, and Masson’s trichrome. The
minimum biopsy size was 20 mm and the number of
portal areas was 10. The liver biopsy specimens were
reviewed by two hepatopathologists (T.O. and Y.S.) who
were blinded to the clinical data. Fatty liver was defined
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while steatohepatitis was diagnosed by steatosis, inflam-
mation, and hepatocyte ballooning [2,3,26]. The indivi-
dual parameters of NASH histology, including fibrosis,
were scored independently using the NASH Clinical
Research Network (CRN) scoring system developed by
the NASH CRN [26]. Advanced fibrosis was classified as
stage 3 or 4 disease (bridging fibrosis or cirrhosis).
Statistical analysis
Statistical analysis was conducted using SPSS 19.0 soft-
ware (SPSS, Inc., Chicago, IL). Continuous variables
were expressed as mean ± standard deviation (SD), or
median (interquartile range). Qualitative data were pre-
sented as numbers with percentages in parentheses. Sta-
tistical differences in quantitative data were determined
using the t test or Mann-Whitney U test. Fisher’s exact
probability test or c
2 analysis was used for qualitative
data (Table 2). The sensitivity and specificity for each
value of each test were calculated to assess the accuracy
of the clinical scoring system in differentiating between
advanced and mild fibrosis, and receiver operating char-
acteristic (ROC) curves were constructed by plotting the
sensitivity against (1 - specificity) at each value (Figure
1). The diagnostic performances of the scoring systems
were assessed by analysis of ROC curves. The most
commonly used index of accuracy was the area under
the ROC curve (AUROC), with values close to 1.0 indi-
cating high diagnostic accuracy. (Table 3). The sensitiv-
ity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated for the
two cut-off values (< 1.45 and > 3.25) proposed by Ster-
ling [22] and those (< 1.30 and > 2.67) proposed by
Shah [24]. Differences were considered statistically sig-
nificant at p < 0.05.
Results
A total of 576 subjects were included in this analysis. Of
these, 280 (49%) were women and 418 (73%) were obese
(Table 2); 241 (42%) had type 2 DM and 184 (32%)
were hypertensive. A total of 319 subjects had steatohe-
patitis, of whom 64 subjects had advanced fibrosis. As
expected, subjects with more advanced fibrosis were sig-
nificantly older, predominantly female, and more likely
to be hypertensive, to have type 2 DM, to have higher
AST, AAR, GGT, FPG, and IRI, and to have lower
hemoglobin, platelet count, albumin, ChE, total choles-
terol, and triglyceride. Regarding the individual compo-
nents of the FIB4 score, the mean (± SD) or median
[interquartile range] values were as follows: age (52.3 ±
15.4 years); AST (43 [30-67] IU/L); ALT (69 [43-112]
IU/L), and platelets (227 ± 67 × 10
9/L) (Table 2). The
distribution of fibrosis stages included stage 0 (n = 263),
stage 1 (n = 169), stage 2 (n = 80), stage 3 (n = 45), and
Table 1 Formulae for determining noninvasive marker panels for detection of liver fibrosis.
Formula Equation
FIB4 index (Age[years] × AST[IU/L])/(platelet count[109/L] ×

ALT[IU/L])
AST to ALT ratio (AAR) AST/ALT
AST to platelet ratio index (APRI)
a ([AST/ULN]/platelet count [10
9/L]) × 100
Age-platelet index (AP index) Age (years) platelet count (10
9/L)
<3 0=0 <2 2 5=0
30-39 = 1 200-224 = 1
40-49 = 2 175-199 = 2
50-59 = 3 150-174 = 3
60-69 = 4 125-149 = 4
≥ 70 = 5 < 125 = 5
Score is the sum of two (0-10)
NAFLD fibrosis score -1.675 + 0.037 × age (years) + 0.094 ×BMI (kg/m
2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT -
0.013 × platelet count (× 10
9/L) - 0.66 × albumin (g/dL).
BARD score Scale 0-4
BMI ≥ 28 kg/m
2 = 1 point
AST/ALT ≥ 0.8 = 2 points
Diabetes = 1 point
N (Nippon) score Scale 0-4
female sex = 1 point
older age (> 60 years) = 1 point
type 2 diabetes = 1 point
hypertension = 1 point
BMI, body mass index; IFG, impaired fasting glucose; INR, international normalized ratio; ULN, upper limit of normal.
aULN for AST: 30 in women, 35 in men.
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a.
Total
(n = 576)
Fibrosis stage 0-2 (n = 512) Fibrosis stage 3-4 (n = 64) p-value
b
Age (yr) 52.3 ± 15.4 51.2 ± 15.5 62.0 ± 10.1 < 0.0001
Gender (female) 280 (49%) 235 (46%) 45 (70%) 0.0003
BMI (kg/m
2) 27.9 ± 4.9 27.8 ± 4.9 28.6 ± 4.8 0.2138
Obesity (BMI > 25) 418 (73%) 369 (72%) 49 (77%) 0.5524
Hypertension (yes) 184 (32%) 150 (29%) 34 (53%) 0.0062
Type 2 diabetes (yes) 241 (42%) 199 (39%) 42 (66%) 0.0001
Hemoglobin (g/dL) 14.6 ± 2.0 14.7 ± 2.0 13.7 ± 2.0 0.0001
Platelet count (×10
9/L) 227 ± 67 235 ± 64 162 ± 52 < 0.0001
AST (IU/L) 43 (30-67) 41 (29-64) 61 (47-77) < 0.0001
ALT (IU/L) 69 (43-112) 69 (43-69) 62 (46-94) 0.5074
AST/ALT ratio 0.65 (0.52-0.82) 0.63 (0.51-0.78) 0.98 (0.73-1.21) < 0.0001
GGT (IU/L) 60 (39-99)
(n = 572)
57 (36-92)
(n = 508)
84 (59-128) < 0.0001
Albumin (g/dL) 4.4 ± 0.4 4.4 ± 0.4 4.1 ± 0.4 < 0.0001
Cholinesterase (IU/L) 380 (330-433)
(n = 527)
385 (337-439)
(n = 466)
297 (244-367)
(n = 61)
< 0.0001
Total cholesterol (mg/dL) 209 ± 40
(n = 467)
210 ± 39
(n = 409)
198 ± 42
(n = 58)
0.0484
Triglyceride (mg/dL) 147 (107-207)
(n = 566)
150 (109-212)
(n = 502)
131 (95-184)
(n = 64)
0.0364
HDL-C (mg/dL) 50 ± 17
(n = 548)
50 ± 17
(n = 487)
51 ± 13
(n = 61)
0.7516
LDL-C (mg/dL) 128 ± 33
(n = 405)
129 ± 32
(n = 363)
120 ± 42
(n = 42)
0.1666
Ferritin (ng/mL) 173 (92-300) 169 (91-292) 216 (128-349) 0.0627
FPG (mg/dL) 103 (94-122)
(n = 524)
103 (94-119)
(n = 462)
111 (95-138)
(n = 62)
0.0166
IRI (μU/mL) 11.6 (7.8-18.4) 11.3 (7.5-17.4) 17.3 (11.3-26.2) < 0.0001
FIB4 index 1.23 (0.77-2.02) 1.13 (0.71-1.79) 3.17 (1.88-4.25) < 0.0001
AST/ALT ratio
(AAR)
0.65 (0.52-0.82) 0.63 (0.51-0.78) 0.98 (0.73-1.21) < 0.0001
AST to platelet ratio index (APRI) 0.61 (0.40-0.98) 0.57 (0.38-0.92) 1.22 (0.86-1.79) < 0.0001
Age-platelet index (AP index) 4 (2-6) 3 (2-5) 7 (5-8) < 0.0001
NAFLD fibrosis score -1.82
(-3.04 to -0.58)
-2.07
(-3.25 to -0.95)
0.25
(-0.60-1.06)
< 0.0001
BARD score < 0.0001
0 144 (25%) 138 (27%) 6 (9%)
1 201 (35%) 194 (38%) 7 (11%)
2 112 (19%) 99 (19%) 13 (20%)
3 88 (15%) 62 (12%) 26 (41%)
4 31 (5%) 19 (4%) 12 (19%)
N score < 0.0001
0 135 (23%) 135 (26%) 0 (0%)
1 170 (30%) 157 (31%) 13 (20%)
2 118 (20%) 96 (19%) 22 (34%)
3 99 (17%) 82 (16%) 17 (27%)
4 54 (9%) 42 (8%) 12 (19%)
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, g-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; FPG, fasting plasma glucose; and IRI, immuno-reactive insulin. a Values are mean ± SD, median (interquartile range), counts (%), as
appropriate. bValues from univariate ordinal logistic regression, Mann-Whitney, or c
2 analysis, as appropriate.
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ged from 0.17-10.74. The median FIB4 score was 1.23
(interquartile range, 0.77-2.02) (Table 3). The mean
(interquartile range) FIB4 indices for stages 0, 1, 2, 3,
and 4 were 1.09 (0.61-1.34), 1.40 (0.77-1.88), 2.36 (1.44-
3.15), 3.23 (1.82-4.04), and 4.48 (3.19-5.17), respectively
(p < 0.0001 by analysis of variance). The mean (inter-
quartile range) FIB4 index was 1.13 (0.71-1.79) in
patients with stage 0-2 fibrosis and 3.17 (1.88-4.25) in
patients with stage 3-4 fibrosis (p< 0.0001) (Table 2).
The sensitivity and specificity of FIB4 along the ROC
were assessed first. At a sensitivity of 90% (FIB4 = 1.45)
the specificity was 35%, while at a specificity of 90%
(FIB4 = 2.67), the sensitivity was 52%. ROC curves were
then developed for each of the noninvasive marker
panels and superimposed, to determine which score
would have the most clinical utility (Figure 1). ROC
curves were created to determine the utility of the
indices for predicting advanced fibrosis (stage 3 and 4
versus lower scores). The AUROC was greatest for FIB4
(0.871), followed by NFS (0.863), APRI (0.823), AP
index (0.810), AAR (0.788), BARD score (0.765), and N
score (0.715) (Table 3). As the NPVs for FIB4 index,
A A R ,A P R I ,A Pi n d e x ,N F S ,B A R Ds c o r e ,a n dNs c o r e
were all greater than 95% using their lower cut-offs,
these tests may have sufficient accuracy to be used clini-
cally to exclude advanced fibrosis. Using this approach,
a significant proportion of patients could avoid liver
biopsy using each of these tests (Table 3). As the PPV
were modest for all noninvasive tests, ranging from 19%
to 53%, it was felt they were not accurate enough to be
used as an alternative to liver biopsy. The PPV for FIB4
is highest among other noninvasive tests.
Using the low cut-off point proposed by Sterling and
colleagues (< 1.45)[22], 330 of 336 (98.3%) patients with-
out stage 3 or 4 fibrosis were correctly staged, while
only 6 (1.7%) were under-staged (Table 4). All of the 6
patients with advanced fibrosis but FIB4 index below
the low cut-off point had stage 3 fibrosis, none had
stage 4 fibrosis. The NPV of this cut-off for stage 3 or 4
fibrosis was 98%. Using the high cut-off point proposed
by Sterling and colleagues (> 3.25) [24], 31 of 59 (52.5%)
patients with stage 3 or 4 fibrosis were correctly staged,
w h i l e2 8( 4 7 . 5 % )w e r eo v e r - s t a g e d .A m o n gt h e2 8
patients without advanced fibrosis but FIB4 index above
the high cut-off point, 18 had stage 2 fibrosis, 6 had
stage 1, and 4 had no fibrosis. The PPV of this cut-off
for stage 3 or 4 fibrosis was 53%. A total of 395 patients
(69% of the cohort) had a FIB4 index < 1.45 or > 3.25;
FIB4 identified the absence or presence of advanced
fibrosis with 91% accuracy in these 361 subjects. A total
of 181 subjects (31%) had FIB4 values in the indetermi-
nate range (1.4-3.25).
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Figure 1 Comparison of ROCs of FIB4 and other panels for the
diagnosis of advanced fibrosis.
Table 3 Accuracy of noninvasive fibrosis marker panels.
Fibrosis panel AUROC Cut-off values Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
FIB4 index 0.871 1.45
3.25
90
48
64
95
24
53
98
94
AST/ALT ratio (AAR) 0.788 0.8
1
66
48
76
92
26
44
95
94
AST to platelet ratio index (APRI) 0.823 1 67 81 31 95
Age-platelet index (AP index) 0.810 6 66 78 27 95
NAFLD fibrosis score 0.863 -1.455
0.676
92
33
63
96
24
50
98
92
BARD score 0.765 2 80 65 22 97
N score 0.715 2 80 58 19 96
AUROC, area under the receiver operating characteristics curve; PPV, positive predictive value; NPV, negative predictive value
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posed by Shah and colleagues (< 1.30) [24], 304 of 308
(99%) patients without stage 3 or 4 fibrosis were cor-
rectly staged, while only 4 (1%) were under-staged
(Table 4). All of the 4 patients with advanced fibrosis
but FIB4 index below the low cut-off point had stage 3
fibrosis and none had stage 4 fibrosis. The NPV of this
cut-off for stage 3 or 4 fibrosis was 99%. Using the high
cut-off point proposed by Shah and colleagues (> 2.67),
38 of 89 (43%) patients with stage 3 or 4 fibrosis were
correctly staged, while 51 (57%) were over-staged.
Among the 51 patients without advanced fibrosis but
NAFLD fibrosis scores above the high cut-off point, 28
had stage 2 fibrosis, 14 had stage 1, and 9 had no fibro-
sis. The PPV of this cut-off for stage 3 or 4 fibrosis was
43%. A total of 397 patients (69% of the cohort) had a
FIB4 index < 1.30 or > 2.67; FIB4 identified the absence
or presence of advanced fibrosis with 86% accuracy in
these 342 subjects. A total of 179 subjects (31%) had
FIB4 values in the indeterminate range (1.30-2.67). Thus
the prevalence of patients in the indeterminate range
was similar using the two different cut-off values, but
the number of patients with true positive or true nega-
tive predictions (accuracy) was higher using Sterling et
al.’s cut-off values compared with Shah et al.’s( 3 6 1
patients versus 342 patients). If liver biopsies were only
performed in patients with an FIB4 index above the low
cut-off point (> 1.45) proposed by Sterling, 336 (58%) of
576 biopsies could be avoided (Table 4).
T h ed i a g n o s t i ca c c u r a c yo fF I B 4i n d e xf o rd e t e c t i n g
advanced fibrosis (stage 3-4) was also compared to that
of NFS (Table 5). Three hundred and seventy patients
(64% of the cohort) had an NFS <-1.455 or > 0.676;
NFS identified the absence or presence of advanced
fibrosis with 93% accuracy in these 344 subjects. A total
of 206 subjects (36%) had NFS values in the indetermi-
nate range (-1.455-0.676). Although the accuracy of NFS
was higher (93%) than that of FIB4 (86%), more patients
were correctly staged with FIB4 (n = 361) than with
NFS (n = 344). Moreover, the percentage of patients in
the undetermined range was lower for the FIB4 index
(31%) than for NFS (36%). Using the cut-off values
reported by Sterling and colleagues, discrepancies
between FIB4 index and NFS were observed in 146
(39%) patients (Table 5). Patients were categorized into
three groups, “low-risk” (< 10%), “intermediate-risk” (10-
30%) and “high-risk” (> 30%), based on the combination
of FIB4 index and NFS (Table 5). Only 1 patient (0.4%)
Table 4 Proportion of patients who may potentially avoid liver biopsy using the simple non-invasive tests to exclude
advanced fibrosis.
Fibrosis panel Cut-off values Patients avoiding liver biopsy
a False negative result
FIB4 index < 1.45 336/576 (58%) 6 (2%)
< 1.30 308/576 (53%) 4 (1%)
AST/ALT ratio (AAR) < 0.8 413/576 (72%) 22 (5%)
AST to platelet ratio index (APRI) < 1 435/576 (76%) 21 (5%)
Age-platelet index (AP index) < 6 421/576 (73%) 22 (5%)
NAFLD fibrosis score < -1.455 328/576 (57%) 5 (2%)
BARD score < 2 355/576 (62%) 13 (4%)
N score < 2 305/576 (53%) 13 (4%)
aPatients with a value below the cut-off.
Table 5 Categorized risk groups for advanced fibrosis according to combined FIB4 index and NAFLD fibrosis score
(NFS).
FIB4 index
(cut-off values proposed by Sterling et al.)
Total
Low cut-off point (< 1.45) Indeterminate
(1.45-3.25)
High cut-off point (> 3.25)
NFS Low cut-off point (<-1.455) 283
[1 (0.4%)]
a
42
[4 (9.5%)]
a
3
[0 (0.0%)]
a
328 (56.9%)
[5 (1.5%)]
Indeterminate (-1.455-0.676) 53
[5 (9.4%)]
a
122
[19 (15.6%)]
b
31
[14 (45.2%)]
c
206 (35.8%)
[38 (18.4%)]
High cut-off point (> 0.676) 0 17
[4 (23.5%)]
b
25
[17 (68.0%)]
c
42 (7.3%)
[21 (50.0%)]
Total 336 (58.3%)
[6 (1.7%)]
181 (31.4%)
[27 (14.9%)]
59 (10.2%)
[31 (52.5%)}
576 (100%)
[64 (11.1%)]
Total number of patients [stage 3-4 (%)]
Patients were categorized into three groups, “low-risk” (< 10%)
a, “intermediate-risk” (10-30%)
b and “high-risk” (> 30%)
c, based on the combination of FIB4 index
and NFS.
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index and NFS had advanced fibrosis.
Discussion
The AUROC of FIB4 was 0.871 for the diagnosis of
advanced fibrosis, which was superior to those of the
other noninvasive panels tested. For a value < 1.45,
fibrosis could be excluded with 98% certainty (NPV
98%) whereas for a value > 3.25, the presence of signifi-
cant fibrosis could be predicted with 53%. Despite the
limited sensitivity of the FIB4 index in a population with
a low prevalence of advanced fibrosis, the score was use-
ful for ruling out advanced fibrosis. In our cohort, 58%
of the liver biopsies could have been avoided if the pro-
cedure was not performed in patients with a FIB4 index
below the low cut-off point (< 1.45). The score would
therefore be particularly useful for reducing the number
of unnecessary liver biopsies performed, and thus the
costs of managing NAFLD patients in Asia, where
advanced fibrosis is uncommon. A high cut-off FIB4
index of 2.67 which has been proposed by Shah and col-
leagues [24] had a low PPV (43%) in predicting stage 3
or 4 fibrosis. Our results contrast with those reported
by Shah and colleagues [24], where a high cut-off FIB4
index of 2.67 had an 80% PPV in predicting stage 3 or 4
fibrosis; however the prevalence of advanced fibrosis in
our study was only 11%, compared to 23% in Shah et
al.’s study. Our study was therefore unable to reliably
validate the high cut-off point, and larger Asian studies
are warranted to investigate this. The FIB4 index was
higher in our population than in Shah et al.’ss t u d y ;
stage 0-2: 1.13 (0.71-1.79) versus 0.97 (0.68-1.37), stage
3-4: 3.17 (1.88-4.25) versus 1.98 (1.28-3.08), probably
because of older age, higher levels of ALT, and lower
levels of platelets in our population.
T h eB A R Ds c o r ed e v e l o p e db yH a r r i s o net al.r e p r e -
sents the weighted sum of three easily available variables
(BMI ≥ 28 kg/m
2 [1 point], AAR ≥ 0.8 [2 points], and
DM [1 point]), and the authors demonstrated that a
score of 2-4 was associated with an odds ratio of 17 for
predicting advanced fibrosis [19]. Although BARD score
is simple to calculate, our validation study failed to
detect any advantage of this score over FIB4; a BARD
score of ≥ 2 was associated with a sensitivity, specificity,
PPV and NPV for detecting advanced fibrosis of 80, 65,
22 and 97%, respectively. Consistent with the present
study, Fujii and colleagues reported significantly poorer
applicability of BARD in Japanese patients with NAFLD,
compared with Caucasian subjects [33]. It has been sug-
gested that BARD score is less predictive of advanced
fibrosis in Japanese NAFLD patients because they are
less obese than those in western countries. The N score
(the total number of the following risk factors: female
sex, age > 60 years, type 2 DM, and hypertension),
which was established on the basis of data from 182
Japanese NAFLD patients in multiple centers in Naga-
saki [20], requires no detailed laboratory measurements,
but was not found to be superior to FIB4 index in our
validation study. Angulo et al. found that the NFS,
which consists of six variables (age, BMI, AAR, IFG/
DM, platelet count, and albumin), reliably predicted
advanced fibrosis in NAFLD patients [21]. In 428 (74%)
of the subjects in the present study, FIB4 index was in
accordance with NFS. The combination of two scoring
systems could help to identify patients likely to have
advanced fibrosis. Patients with FIB4 values above the
high cut-off point (> 3.25) and NFS values above the
low cut-off point (> -1.455) were at high risk (> 30%)
for advanced fibrosis. If both FIB4 and NFS were
applied to Japanese patients with NAFLD, patients with
either FIB4 or NFS values below the low cut-off points
(376/576, 65.3%) could avoid liver biopsies. In this way,
when FIB4 was combined with NFS, its ability to predict
or exclude advanced fibrosis improved further. In sum-
mary, the current study demonstrated that the FIB4
index, which can be established using a simple, relatively
inexpensive method, correlated with the stage of fibrosis
in adult subjects with NAFLD.
Type IV collagen is one of extracellular matrices that
are produced by hepatic fibroblasts. The 7S domain in
the N-terminus of type IV collagen is inserted in tissues
and released into the blood by turnover in connective
tissues. Therefore, the serum 7S domain level increases
in parallel with the amount of fibrosis and in synthesis
from stellate cells and myofibroblasts following
increased liver fibrosis. In Japan, type IV collagen 7S is
now widely used for assessing the extent of hepatic
fibrosis in chronic liver diseases. Our data demonstrated
that a cutoff point of 5.4 ng/ml provided a sensitivity
and specificity of 86% and 87%, respectively, to detect
advanced stage of NASH. The AUROC of type IV col-
lagen 7s was: 0.926 for the diagnosis of advanced fibro-
sis, which was superior to FIB4 (data not shown). This
data suggest that type IV collagen 7S is one of the best
parameters among non-invasive parameters, but it costs
too much to be determined routinely.
On the other hand, hepatic steatosis is frequently
found in patients with HCV infection. Therefore, we
also evaluated the value of FIB4 index in 185 HCV-
infected patients with hepatic steatosis, including those
with 72 advanced and 113 mild fibrosis. The AUROC of
FIB4 was 0.808 for the diagnosis of advanced fibrosis.
For a value < 1.45, fibrosis could be excluded with 89%
certainty (NPV 89%) whereas for a value > 3.25, the pre-
sence of advanced fibrosis could be predicted with 82%
(data not shown).
This study had several limitations. First, the propor-
tion of subjects with advanced fibrosis was small, as
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studies with more patients with advanced fibrosis are
warranted. Second, patients were recruited from hepa-
tology centers in Japan with a particular interest in
studying NAFLD, and the possibility of some referral
bias could therefore not be ruled out. Patient selection
bias could also have existed, because liver biopsy might
have been considered for NAFLD patients who were
likely to have NASH. The findings may thus not repre-
sent NAFLD patients in the wider community. However,
this would introduce a negative bias, as NAFLD patients
in the community would be likely to have milder liver
disease, thus increasing the NPV of the FIB4 index. We
also acknowledge that pathologic diagnosis was mainly
determined using liver tissues derived from percuta-
neous liver biopsies, which are prone to sampling errors
or interobserver variability [7,8]. As recent studies sug-
gest that low normal ALT value does not guarantee
freedom from underlying NASH with advanced fibrosis
[35-37], it remains to be solved whether FIB4 index can
be useful for predicting advanced fibrosis in NAFLD
subjects with normal ALT. According to our preliminary
data by JSG-NAFLD, the AUROC of FIB4 was 0.810 for
the diagnosis of advanced fibrosis in 187 biopsy-proven
NAFLD patients with normal ALT levels (data not
shown). Our data support the hypothesis that FIB4
index could also be used in the Japanese NAFLD popu-
lation with normal ALT.
Conclusion
The FIB4 index demonstrated a good NPV for excluding
advanced fibrosis in Japanese NAFLD patients, and
could thus be used to reduce the burden of liver biop-
sies. Larger Asian studies are required to validate the
high cut-off point of the FIB4 index. However, the FIB4
test also has several serious limitations, in common with
other noninvasive tests for fibrosis, and further research
is needed before simple noninvasive tests, including the
FIB4 test, can replace liver biopsies in the vast majority
of patients.
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